Search clinical trials for: Cyclin-Dependent Kinase Inhibitor Proteins

Total 11855 results

Boehringer Ingelheim

Approved for marketing

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Xuzhou Central Hospital

Unknown

Apatinib for Advanced Lung Squmamous Carcinoma

Lung Squamous Cell Carcinoma
Cancer Research UK

Terminated

A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours (AZD0424)

Advanced Solid Tumours

United Kingdom
Hebei Medical University Fourth Hospital

Unknown

Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer

Breast Cancer Metastatic

China
Massachusetts General Hospital
Bristol-Myers Squibb; Dana-Farber Cancer Institute; Brigham and Women's Hospital

Completed

Dasatinib in Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Anhui Provincial Hospital

Unknown

Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer

Two Different Treatment Methods

China
Boehringer Ingelheim

Terminated

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

Carcinoma, Non-Small-Cell Lung | ErbB Receptors

United States
Groupe Hospitalier Paris Saint Joseph

Withdrawn

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex (THEN)

SMALL CELL LUNG CARCINOMA

France
Jean M. Tersak, M.D.
Pfizer

No longer available

Treatment With Crizotinib Single Patient Expanded Access IND 134375

Inflammatory Myofibroblastic Tumour
Shanghai Zhongshan Hospital

Unknown

Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection

Carcinoma, Hepatocellular

China
Pfizer

Terminated

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Spain, Korea, Republic of, Taiwan, Canada, Poland, Belgium, Denmark, Germany, Serbia, United Kingdom, France, Czechia, Hungary, Mexico, Colombia, Russian Federation, Croatia, Singapore, Australia, Austria, Slovakia, S... and more
OncoTherapy Science, Inc.

Completed

Phase 1 Study of OTS167 in Patients With Solid Tumors

Solid Tumors | Metastatic Tumors

United States
Junling Li

Unknown

The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer

Apatinib in Maintenance Treatment

China
Yale University

Completed

Tofacitnib for the Treatment of Alopecia Areata and Variants

Alopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)

United States
Samsung Medical Center

Completed

Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer

HER2-positive Refractory Advanced Cancer

Korea, Republic of
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Ponatinib for Advanced Medullary Thyroid Cancer

Thyroid Neoplasms

United States
Hangzhou Cancer Hospital

Unknown

Apatinib for Metastatic Esophageal Cancer.

Esophageal Cancer | Apatinib | Metastatic Esophageal Cancer

China
Peking University Cancer Hospital & Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients

Hepatocellular Carcinoma

China
Huashan Hospital

Unknown

Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease

Cushing's Disease | Corticotrophin Adenoma

China
Pfizer

Completed

Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers

Healthy

United Kingdom
Pfizer

Withdrawn

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Pfizer

Completed

Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

Renal Impairment

United States
University of Turin, Italy

Unknown

Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM) (SORHORM)

Kidney Cancer | Liver Cancer

Italy
King's College London
Bayer

Unknown

Sorafenib in Previously Treated Malignant Mesothelioma (SMS)

Mesothelioma

United Kingdom
AstraZeneca
Cancer International Research Group (CIRG)

Completed

Ph II Early BC Pre-Surgical Biologic Study

Breast Cancer
AstraZeneca

Completed

Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy

Prostate Cancer

Finland
AstraZeneca

Completed

A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United Kingdom, Denmark
Tang-Du Hospital

Recruiting

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

EGF-R Positive Non-Small Cell Lung Cancer | CNS Metastases

China
Helwan University

Not yet recruiting

Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. (Palbociclib)

Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone-receptor-positive Breast Cancer
Bristol-Myers Squibb

Not yet recruiting

Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Moderate-to-severe Plaque Psoriasis

Korea, Republic of
Juan LI, MD

Recruiting

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Non Small Cell Lung Cancer | EGFR Exon 20 Insertion Mutation

China
Pusan National University Hospital
Yuhan Corporation

Not yet recruiting

Impact of Lazertinib Dose Modification on Effectiveness and Safety

Non-small Cell Lung Cancer

Korea, Republic of
Huashan Hospital
Boehringer Ingelheim

Not yet recruiting

Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma

Chordoma of Clivus

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations

China
Yonsei University

Recruiting

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

Non Small Cell Lung Cancer

Korea, Republic of
Jun Zhang, MD, PhD
University of Iowa; University of Kentucky

Recruiting

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung)

NSCLC Stage IV | NSCLC Stage IIIB

United States
Shenzhen Second People's Hospital

Recruiting

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

Chronic Myeloid Leukemia | Dasatinib | BCR-ABL

China
Fundación Teófilo Hernando, Spain

Recruiting

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Spain
University Hospital, Basel, Switzerland

Recruiting

Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (NINBOST2018)

Bronchiolitis Obliterans Syndrome (BOS) | Bronchiolitis Obliterans (BO)

Switzerland, Saudi Arabia
Canadian Cancer Trials Group
Pfizer

Active, not recruiting

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Canada
Intergroupe Francophone de Cancerologie Thoracique

Active, not recruiting

Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL)

Non Small Cell Lung Cancer Metastatic | Brain Metastases | EGFR Activating Mutation | Leptomeningeal Metastasis

France
Pfizer

Completed

UK Ibrance Patient Program (IPP) Study (ROIS)

HR+/HER2- Locally Advanced, Metastatic Breast Cancer

United Kingdom
Shanghai Pulmonary Hospital, Shanghai, China

Completed

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation | Lung Adenocarcinoma Stage III

China
Shanghai Zhongshan Hospital

Completed

Effect of Tofacitinib in Treating ANCA-associated Vasculitis

Drug Use | ANCA Associated Vasculitis | JAK-STAT Pathway Deregulation

China
Asan Medical Center
AstraZeneca

Completed

TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy

NSCLC

Korea, Republic of
Washington University School of Medicine

Active, not recruiting

Tofacitinib for Inflammatory Eye Disease

Uveitis | Scleritis

United States
Memorial Sloan Kettering Cancer Center

Completed

Nintedanib in Patients With Advanced Esophagogastric Cancer

Esophagogastric Adenocarcinoma

United States
Boehringer Ingelheim

Completed

Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy (LUX-Bladder 1)

Urologic Neoplasms

Spain, France, Italy
Sun Yat-sen University

Withdrawn

Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Boehringer Ingelheim

Completed

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Carcinoma, Non-Small-Cell Lung | ErbB Receptors

United States

Search clinical trials for: Cyclin-Dependent Kinase Inhibitor Proteins

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations